. 2023 Nov 20;23:403. doi: 10.1186/s12876-023-03047-0

Table 2.

Clinical trials comprising patients with HCC and developing pulmonary metastases after TIPS placement

Author	Study type	Enrolled patients	Liver malignancy	Shunts traversing the tumour	Cases with pulmonary metastases post TIPS	Time between TIPS placement and diagnosis of pulmonary metastases (months)
Tsauo J, et al. 2021 [17]	Retrospective, single-centre	126	HCC (n = 126)	8	3, amongst them no shunt traversing the tumour	3.9–32.9
Zhao H, et al. 2018 [39]	Systematic review	280	HCC (n = 280)	35	2	5 and 72
Wallace M, et al. 2003 [67]	Case series	9	HCC (n = 7) Pancreatic neuroendocrine metastases (n = 1) Metastatic gastrointestinal stroma tumour (n = 1)	9	2	5 and 10

Author

Study type

Enrolled patients

Liver malignancy

Shunts traversing the tumour

Cases with pulmonary metastases post TIPS

Time between TIPS placement and diagnosis of pulmonary metastases (months)

Tsauo J, et al. 2021 [17]

Retrospective, single-centre

126

HCC (n = 126)

3, amongst them no shunt traversing the tumour

3.9–32.9

Zhao H, et al. 2018 [39]

Systematic review

280

HCC (n = 280)

5 and 72

Wallace M, et al. 2003 [67]

Case series

HCC (n = 7)

Pancreatic neuroendocrine metastases (n = 1)

Metastatic gastrointestinal stroma tumour (n = 1)

5 and 10

TIPS: transjugular intrahepatic portosystemic shunt; HCC: hepatocellular carcinoma